AlanCharlesHartfordMDPhD, FACR

Radiation Oncology • Fitchburg, MA

Professor of Medicine (Radiation Oncology), Geisel School of Medicine at Dartmouth

Join to view full profile

Dr. Hartford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hartford's full profile

Already have an account?

Office
275 Nichols Rd
Fitchburg, MA 01420
Phone+1 978-343-5196

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 1993 - 1997
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1992 - 1993
Harvard Medical SchoolClass of 1992

Certifications & Licensure

MA State Medical License 1996 - 2026
NH State Medical License 2004 - 2026
VT State Medical License 2007 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 3
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
Completed
Phase 1, Phase 2
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer Start of enrollment: 2009 Nov 01
Completed
Phase 2
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 01
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
A Proof-of-principle Study of HBO-SRS for Brain Metastases Start of enrollment: 2013 Jul 01
Completed
Not Applicable
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Artificial Intelligence for Prostate Cancer Treatment Planning Start of enrollment: 2020 Jun 22
Completed
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu
Journal of Clinical Oncology. 2024-12-01
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Krishnan R Patel, Paul L Nguyen, James A Proudfoot, Yang Liu, Alan Dal Pra
European Urology Oncology. 2024-11-13
4 citations
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
Ashley E Ross, Jingbin Zhang, Huei-Chung Huang, Rikiya Yamashita, Jessica Keim-Malpass
European Urology Oncology. 2024-10-01

Authored Content

ACR 2021 in BriefMay 2021
Perspectives from Council of Affiliated Regional Radiation Oncology SocietiesJune 2019
Perspectives from Council of Affiliated Regional Radiation Oncology SocietiesJune 2019

Press Mentions

Dr. Alan Hartford Selected to Be Inducted into IAOTP’s Hall of FameSeptember 6th, 2021
ACR 2021 in BriefMay 24th, 2021
Dartmouth Physician-Scientists Examine Efficacy of Radiation Therapy in 'Good-Risk' DCIS PatientsFebruary 12th, 2016